Breaking News, Collaborations & Alliances

Ipsen, University of Texas Enter Agreement

For a pre-clinical oncology drug candidate discovered by researchers in MD Anderson’s Institute for Applied Cancer Science

Ipsen and The University of Texas MD Anderson Cancer Center today announced a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by researchers in MD Anderson’s Institute for Applied Cancer Science (IACS). MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization. Alexandre Lebeaut, M.D., executive vice president, Research & Dev...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters